Raafat Attia Hanna
Endocrinology, Diabetes & Metabolism · Plymouth, MANPI 1922150804
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 307 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,009 and has fallen 96.9% since, to $62 in 2024.
Across 307 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$806
- Johnson & Johnson$676
- AbbVie$520
- Boehringer Ingelheim$517
- AstraZeneca$373
- Novo Nordisk$280
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,75297%
- Education$1513%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 54 | $806 |
| Johnson & Johnson | 51 | $676 |
| AbbVie(2 entities) | 48 | $520 |
| Boehringer Ingelheim | 27 | $517 |
| AstraZeneca(2 entities) | 22 | $373 |
| Novo Nordisk | 13 | $280 |
| Sanofi-aventis U.S. LLC | 10 | $202 |
| Lilly USA, LLC | 10 | $182 |
| Merck | 11 | $178 |
| Amarin Pharma, Inc. | 10 | $161 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $110 |
| Novartis | 7 | $107 |
| Antares Pharma, Inc. | 5 | $99 |
| Insmed, Inc. | 2 | $94 |
| Astellas Pharma US Inc | 3 | $89 |
| Exact Sciences | 1 | $62 |
| Eisai Inc. | 3 | $58 |
| Kowa Pharmaceuticals America, Inc. | 4 | $58 |
| Valeritas, Inc. | 3 | $56 |
| E.r. Squibb & Sons, L.L.C. | 3 | $51 |
| Amgen | 2 | $36 |
| Ultragenyx Pharmaceutical Inc. | 2 | $34 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Clarus Therapeutics Inc. | 2 | $24 |
| Abbott | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $21 |
| Shire North American Group Inc | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$4,903 in reported general payments places this provider in the 75th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Other endocrinology, diabetes & metabolism in Plymouth
- Jason GagliaBoston$2.4M
- Tamer YacoubFall River$775K
- Vanita ArodaBoston$482K
- Michael RosenblattBoston$447K
- Steven RussellBoston$445K
- Nitin TrivediWorcester$403K
- Beverly BillerBoston$346K
- Christos MantzorosBoston$243K
- Peter ButlerFlorence$216K
- Augusto Caballero-RoblesBoston$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.